The Trump administration announced it will let Medicare Part D prescription drug subsidies expire at year's end, a move officials say targets corporate insurance bailouts but that could raise premiums for tens of millions of seniors and disabled Americans.
Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz framed the decision as a market correction, posting on X that the government has been propping up insurance companies with billions in taxpayer dollars under a program created by the Inflation Reduction Act. The subsidies, which the government pays directly to insurers to keep monthly premiums low for Medicare Part D enrollees, will not be renewed. Changes to prescription drug plan costs are expected to take effect in 2027, with enrollees set to learn their new monthly rates later this fall.
ABC News reported the announcement Tuesday, noting that the Wall Street Journal first broke the news. The decision lands on a health care landscape already rattled by the expiration of separate Affordable Care Act marketplace subsidies, a lapse that has driven insurance costs sharply higher for millions of working-age Americans.
Oz moved quickly to get ahead of the political fallout. In his X post, the CMS administrator argued that the Inflation Reduction Act had effectively "bailed out" major insurance companies while premiums kept climbing, a pattern conservatives have cited for years as evidence that government subsidies inflate costs rather than contain them.
Oz wrote:
"We are stabilizing the market so this bailout is no longer needed. Premiums will go up by less than $10 for most Medicare recipients, with many even seeing LOWER premiums."
He added that every Medicare beneficiary will still have access to low-cost plans and pointed to additional administration efforts to bring down drug prices, including "most favored nation" deals, agreements under which pharmaceutical companies charge American patients the same rates they charge in other countries, and a policy offering seniors access to GLP-1 weight-loss and diabetes drugs for $50 a month.
A Trump administration official told reporters that roughly half of enrollees will either see a premium increase of less than $10 per month or will actually see their premiums drop. Most enrollees, the official said, will have plans available at $10 or less per month.
Not every estimate lines up with the administration's projections. KFF, a widely cited health policy nonprofit, currently puts the average Medicare Part D premium at about $36 per person per month. The group has projected that ending the subsidies could push premiums up by as much as $20 a month for some enrollees, a figure roughly double the administration's claim for most recipients.
The gap between those numbers matters. Medicare Part D covers tens of millions of older and disabled Americans, many of them on fixed incomes. A $20 monthly increase may sound modest in Washington budget terms, but for a retiree managing prescription costs alongside rising grocery and utility bills, it is a concrete hit to the household bottom line.
An administration official acknowledged that the move will likely result in higher prescription costs and increased premiums for about half of recipients. That concession sits uneasily beside Oz's more optimistic framing, though the administration argues the other half will see costs stay flat or fall.
The Medicare Part D decision does not exist in isolation. It arrives after a bruising political fight over separate ACA marketplace subsidies that expired late last year during a 43-day government shutdown. Those enhanced subsidies, first created under Biden's American Rescue Plan and extended through the Inflation Reduction Act, had lowered out-of-pocket premium costs for millions of Americans buying insurance on the federal marketplace.
When those subsidies lapsed, the impact was immediate and severe. Average annual health insurance costs rose 114 percent for previously subsidized enrollees, according to AP News. The House later passed a bill to extend the ACA subsidies for three years on a 230-196 vote, with 17 Republicans breaking from party leadership to join every Democrat, a rare bipartisan rebuke of House Speaker Mike Johnson. The Congressional Budget Office estimated the extension would cost $80.6 billion over a decade but expand insurance coverage by up to four million people by 2028.
That bill now sits in the Senate, where a bipartisan group is working on a compromise plan. But the political dynamics are clear: health care costs are climbing, voters are feeling the squeeze, and both parties know it.
The Trump administration's case against the Medicare Part D subsidies echoes a broader conservative critique that has gained traction over the past decade. Government payments to insurers, the argument goes, do not actually reduce costs, they mask them while giving carriers less incentive to compete on price. The result is a system where premiums keep rising and taxpayers keep covering the difference.
House Ways and Means Committee Chair Jason Smith has pointed out that ObamaCare marketplace premiums have increased 80 percent since the program launched a decade ago, Fox News reported. That trajectory undermines the progressive claim that subsidies are a net benefit, if premiums keep climbing even as the government pours billions into the system, the subsidies start to look less like relief for patients and more like a guaranteed revenue stream for insurers.
KFF's Cynthia Cox has pushed back on that framing, arguing that the tax credits "do not have an inflationary effect on insurance premiums" and in fact exert "a downward effect on insurance and the amount that the insurance company is charging." That claim deserves scrutiny. If subsidies hold premiums down, the 80 percent increase over the past decade demands an explanation for what would have happened without them, and whether the answer justifies billions in annual spending.
When the Biden administration signed the Inflation Reduction Act, officials promoted it as a landmark achievement that would allow the government to negotiate directly with pharmaceutical companies on pricing for some of the most expensive medicines. The law also created the Medicare Part D subsidy structure that the Trump administration is now dismantling.
Trump officials see a different legacy. They argue the IRA funneled taxpayer money to insurance companies under the guise of helping seniors, while premiums continued to rise. Oz's characterization of the subsidies as a "bailout" is pointed, it reframes the Democratic talking point of affordability as a story about corporate welfare.
Whether that framing holds depends on what happens next. If premiums spike sharply in 2027 and seniors scramble to find affordable plans, the administration will own the consequences. If competition drives costs down and most enrollees land in plans at $10 or less, as officials project, the decision will look like a vindication of market-based reform.
For the tens of millions of Americans enrolled in Medicare Part D, the most immediate reality is uncertainty. The administration says enrollees will learn their new monthly costs "later this fall," which means months of waiting before seniors and disabled beneficiaries know how much more, or less, they will pay for prescription drug coverage in 2027.
Several questions remain unanswered. The administration has not specified the total dollar amount of subsidies currently flowing to insurers, beyond "billions." It has not defined what "most" enrollees means when projecting that premiums will rise less than $10 for the majority. And it has not detailed how the "most favored nation" deals or the $50-a-month GLP-1 policy will offset the loss of direct premium subsidies for enrollees who depend on them.
The political stakes are plain. Health care costs consistently rank among the top concerns for older voters, the very demographic that forms the backbone of the Republican coalition. If seniors feel blindsided by higher bills, the backlash will not be abstract. It will show up at the ballot box.
Government has spent years subsidizing insurance companies and calling it compassion. The Trump administration is betting that ending the payments and forcing the market to compete will do more for seniors than another round of billion-dollar checks to corporate carriers ever did. The answer will arrive in every enrollee's mailbox this fall.
